Clinical Trial Update: Clinical Trial of PCV24 in Children Aged 2-17 Years [Phase 1]

View source ↗

Summary

Phase 1 trial of PCV24 in children aged 2-17 years has completed, assessing safety and initial dosing for pneumococcal disease. The study is sponsored by Sinova…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• PCV24 (24-valent pneumococcal conjugate vaccine)

Snippet

Sponsor: Sinovac Life Sciences Co., Ltd. | Conditions: Pneumococcal Infectious Disease | Phase 1 | Status: COMPLETED